泛素受体PSMD4/Rpn10是多发性骨髓瘤的新治疗靶点
研究显示Rpn10在骨髓瘤细胞中高表达且与总生存负相关,敲除或抑制Rpn10可诱导多聚泛素化蛋白聚集、细胞周期停滞和凋亡,并增强自噬与免疫激活。新鉴定的Rpn10抑制剂SB699551在体外和异种移植模型中降低骨髓瘤细胞活力、克服蛋白酶体抑制剂耐药并延长生存,且不影响正常外周血单核细胞活力。
要点
- Rpn10在骨髓瘤细胞中较正常浆细胞高表达,其水平与患者总生存呈负相关。
- 诱导性敲除或敲低Rpn10通过多聚泛素化蛋白积累、细胞周期停滞和凋亡降低骨髓瘤细胞活力。
- 新抑制剂SB699551不阻断20S蛋白酶体催化功能或19S去泛素化活性,可克服蛋白酶体抑制剂耐药。
核心结论
- 抑制Rpn10可增强细胞毒性并克服多发性骨髓瘤中的蛋白酶体抑制剂耐药,为Rpn10抑制剂的进一步优化研究提供基础。
研究设计与样本
- 研究采用体外细胞实验、体内异种移植模型及高通量AlphaScreen结合试验筛选Rpn10抑制剂。
主要发现
- Rpn10在骨髓瘤细胞中较正常浆细胞高表达,其水平与患者总生存呈负相关。
- 诱导性敲除或敲低Rpn10通过触发多聚泛素化蛋白积累、细胞周期停滞及凋亡降低骨髓瘤细胞活力。
- 蛋白组学分析显示抑制Rpn10增加自噬、抗原提呈及CD4+ T细胞和自然杀伤细胞活化。
- SB699551降低骨髓瘤细胞系、白血病细胞系及患者原代细胞活力,但不影响正常外周血单核细胞活力。
- 在骨髓瘤异种移植模型中,SB699551耐受良好、抑制肿瘤生长并延长生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PSMD4/Rpn10 is a subunit of the 19S proteasome unit that is involved with feeding target proteins into the catalytic machinery of the 26S proteasome. Because proteasome inhibition is a common therapeutic strategy in multiple myeloma (MM), we investigated Rpn10 and found that it is highly expressed in MM cells compared with normal plasma cells. Rpn10 levels inversely correlated with overall survival in patients with MM. Inducible knockout or knockdown of Rpn10 decreased MM cell viability both in vitro and in vivo by triggering the accumulation of polyubiquitinated proteins, cell cycle arrest, and apoptosis associated with the activation of caspases and unfolded protein response-related pathways. Proteomic analysis revealed that inhibiting Rpn10 increased autophagy, antigen presentation, and the activation of CD4+ T and natural killer cells. We developed an in vitro AlphaScreen binding assay for high-throughput screening and identified a novel Rpn10 inhibitor, SB699551 (SB). Treating MM cell lines, leukemic cell lines, and primary cells from patients with MM with SB decreased cell viability without affecting the viability of normal peripheral blood mononuclear cells. SB inhibited the proliferation of MM cells even in the presence of the tumor-promoting bone marrow milieu and overcame proteasome inhibitor (PI) resistance without blocking the 20S proteasome catalytic function or the 19S deubiquitinating activity. Rpn10 blockade by SB triggered MM cell death via similar pathways as the genetic strategy. In MM xenograft models, SB was well tolerated, inhibited tumor growth, and prolonged survival. Our data suggest that inhibiting Rpn10 will enhance cytotoxicity and overcome PI resistance in MM, providing the basis for further optimization studies of Rpn10 inhibitors for clinical application.
引用
- Du T, Song Y, Ray A, et al. Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma. Blood. 2023. PMID: 36630605. doi:10.1182/blood.2022017897
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。